clinical trial · NCT05492994
A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
Boehringer Ingelheim·N/A·active not recruiting·n = 31
Lung Diseases, InterstitialSpirometryDiffusing Capacity of the Lung for Carbon Monoxide (DLCO)Magnetic Resonance ImagingChest Computer TomographyBlood biomarker analysis
brief summary
The main objectives of this imaging biomarker study are to assess the annual lung function change in patients with progressive fibrosing interstitial lung disease (PF-ILD) including idiopathic pulmonary fibrosis (IPF), with Usual Interstitial Pneumonia (UIP) or probable UIP Computer Tomography (CT) pattern, and to monitor lung structural changes.
started
Dec 19, 2022
primary completion
Jun 9, 2026
completion
Jun 9, 2026
last updated
Aug 5, 2025
official title
Longitudinal Study Without an Investigational Medicinal Product in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to Evaluate Novel Imaging-based Biomarkers in Comparison With Lung Function for Use in Early Clinical Development
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol